Skip to content
lifestyle.side.cr
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Decoy Therapeutics, Inc
/C O R R E C T I O N — Decoy Therapeutics, Inc/
September 22, 2026
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
September 22, 2026
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
September 22, 2026
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
August 3, 2026
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
July 27, 2026
Decoy Therapeutics’ CEO to Participate in hVIVO Capital Markets Day in London
June 8, 2026
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
June 3, 2026
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
June 1, 2026
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
May 26, 2026
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
April 27, 2026
1
2
Next Page
→